Immuno-Biological Laboratories Co., Ltd. (4570.T)
JPY 449.0
(2.05%)
JPY 449.0
(2.05%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 128.1 Million JPY | 183.2% |
| 2022 | -332 Million JPY | 44.89% |
| 2021 | -249.5 Million JPY | 14.47% |
| 2020 | -309.88 Million JPY | -393.51% |
| 2019 | -63 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 52.5 Million JPY | -40.82% |
| 2023 Q3 | -4.71 Million JPY | -127.12% |
| 2023 Q1 | 6.99 Million JPY | 109.34% |
| 2023 Q4 | 99.92 Million JPY | 2218.87% |
| 2023 FY | - JPY | 183.2% |
| 2023 Q2 | 17.38 Million JPY | 148.52% |
| 2022 Q3 | -10 Million JPY | 72.97% |
| 2022 FY | - JPY | 44.89% |
| 2022 Q4 | -74.9 Million JPY | -649.0% |
| 2022 Q2 | -37 Million JPY | 0.0% |
| 2021 FY | - JPY | 14.47% |
| 2020 FY | - JPY | -393.51% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 86.629% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | 126.244% |
| GNI Group Ltd. | 14.48 Billion JPY | 99.116% |
| Linical Co., Ltd. | 1.24 Billion JPY | 89.729% |
| Trans Genic Inc. | 240.95 Million JPY | 46.833% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 109.448% |
| Soiken Holdings Inc. | -583.2 Million JPY | 121.966% |
| Cytori Cell Research Institute, Inc. | -603.09 Million JPY | 121.242% |
| AnGes, Inc. | -8.86 Billion JPY | 101.446% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 109.966% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 101.731% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 114.844% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 111.734% |
| CanBas Co., Ltd. | 53.65 Million JPY | -138.778% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 116.517% |
| RaQualia Pharma Inc. | -111.8 Million JPY | 214.585% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 110.572% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 109.278% |
| PeptiDream Inc. | 7.37 Billion JPY | 98.263% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 106.639% |
| Ribomic Inc. | -1.01 Billion JPY | 112.652% |
| SanBio Company Limited | -4.52 Billion JPY | 102.831% |
| Healios K.K. | -3 Billion JPY | 104.26% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 110.989% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 109.196% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 109.137% |
| StemRIM | -2.03 Billion JPY | 106.304% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 90.194% |
| FunPep Company Limited | -952 Million JPY | 113.457% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 114.414% |
| Stella Pharma Corporation | -723.85 Million JPY | 117.698% |
| TMS Co., Ltd. | -937 Million JPY | 113.672% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 116.522% |
| Cuorips Inc. | -518 Million JPY | 124.731% |
| K Pharma,Inc. | 366.05 Million JPY | 65.004% |
| Takara Bio Inc. | 8.02 Billion JPY | 98.403% |
| ReproCELL Incorporated | 8.24 Million JPY | -1453.754% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | -45.679% |
| StemCell Institute Inc. | 534.35 Million JPY | 76.026% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 47.672% |
| CellSeed Inc. | -836.51 Million JPY | 115.314% |